Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors

Myelo fi brosis (MF) is caused by expansion of mutated hematopoietic stem and progenitor cells that results in bone marrow (BM) fi brosis, ineffective erythropoiesis, elevated in fl am-matory cytokines, and extramedullary hematopoiesis. Most MF patients experience constitutional symptoms that impair quality of life. Cytop...

S. Tantravahi, Andrea A Ellero, Ami B. Patel et al. · 1 citation
Jul 2026

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment-related pathways.

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional symptoms, marrow fibrosis, cytopenias and inflammation. Janus kinase 2 (JAK2) inhibitors, such as ruxolitinib, reduce splenomegaly and alleviate symptoms but have limited disease-modifying activity, and resis...

T. Kashyap, Andrea A Ellero, C. Walker et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.